Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 5
2010 8
2011 6
2012 9
2013 36
2014 36
2015 50
2016 60
2017 40
2018 56
2019 65
2020 72
2021 76
2022 57
2023 5
Text availability
Article attribute
Article type
Publication date

Search Results

511 results
Results by year
Filters applied: . Clear all
Page 1
Pulmonary Hypertension: A Brief Guide for Clinicians.
Mandras SA, Mehta HS, Vaidya A. Mandras SA, et al. Mayo Clin Proc. 2020 Sep;95(9):1978-1988. doi: 10.1016/j.mayocp.2020.04.039. Mayo Clin Proc. 2020. PMID: 32861339 Free article. Review.
Targeted treatments (phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, endothelin receptor antagonists, prostacyclin analogues, and prostacyclin receptor agonists) are licensed for patients with PAH. The soluble guanylate cyclase stimulator riociguat
Targeted treatments (phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, endothelin receptor antagonists, prostacycl …
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
Ruopp NF, Cockrill BA. Ruopp NF, et al. JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402. JAMA. 2022. PMID: 35412560 Review.
Currently approved therapy for PAH consists of drugs that enhance the nitric oxide-cyclic guanosine monophosphate biological pathway (sildenafil, tadalafil, or riociguat), prostacyclin pathway agonists (epoprostenol or treprostinil), and endothelin pathway antagonists (bos …
Currently approved therapy for PAH consists of drugs that enhance the nitric oxide-cyclic guanosine monophosphate biological pathway (silden …
Update of EULAR recommendations for the treatment of systemic sclerosis.
Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors. Kowal-Bielecka O, et al. Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9. Ann Rheum Dis. 2017. PMID: 27941129 Free article.
Compared with the 2009 recommendations, the 2016 recommendations include phosphodiesterase type 5 (PDE-5) inhibitors for the treatment of SSc-related RP and DUs, riociguat, new aspects for endothelin receptor antagonists, prostacyclin analogues and PDE-5 inhibitors for SSc …
Compared with the 2009 recommendations, the 2016 recommendations include phosphodiesterase type 5 (PDE-5) inhibitors for the treatment of SS …
Chronic thromboembolic pulmonary hypertension.
Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, Ogo T, Tapson VF, Ghofrani HA, Jenkins DP. Kim NH, et al. Eur Respir J. 2019 Jan 24;53(1):1801915. doi: 10.1183/13993003.01915-2018. Print 2019 Jan. Eur Respir J. 2019. PMID: 30545969 Free PMC article. Review.
For technically inoperable cases, PH-targeted medical therapy is recommended (currently riociguat based on the CHEST studies), and balloon pulmonary angioplasty should be considered at a centre experienced with this challenging but potentially effective and complementary i …
For technically inoperable cases, PH-targeted medical therapy is recommended (currently riociguat based on the CHEST studies), and ba …
Clinical Review Report: Riociguat (Adempas) [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Dec. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Dec. PMID: 30869848 Free Books & Documents. Review.
The objective of this systematic review is to evaluate the beneficial and harmful effects of riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg tablets for the treatment of pulmonary arterial hypertension in adults (World Health Organization [WHO] functional class II or III) …
The objective of this systematic review is to evaluate the beneficial and harmful effects of riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg, an …
Chronic Thromboembolic Disease and Chronic Thromboembolic Pulmonary Hypertension.
Lang IM, Campean IA, Sadushi-Kolici R, Badr-Eslam R, Gerges C, Skoro-Sajer N. Lang IM, et al. Clin Chest Med. 2021 Mar;42(1):81-90. doi: 10.1016/j.ccm.2020.11.014. Epub 2021 Jan 12. Clin Chest Med. 2021. PMID: 33541619 Free article. Review.
CTEPH and CTED can be near-cured by pulmonary endarterectomy, balloon pulmonary angioplasty, and medical treatment with Riociguat or subcutaneous treprostinil, which are the approved drugs....
CTEPH and CTED can be near-cured by pulmonary endarterectomy, balloon pulmonary angioplasty, and medical treatment with Riociguat or …
Pharmacoeconomic Review Report: Riociguat (Adempas) [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Dec. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Dec. PMID: 30998298 Free Books & Documents. Review.
Riociguat (Adempas) is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1), as monotherapy or in combination with endothelin receptor antagonists (ERAs) in adult p
Riociguat (Adempas) is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of pulmonary arterial hyperten
Riociguat (Adempas): Management of Inoperable Chronic Thromboembolic Pulmonary Hypertension [Internet].
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul. PMID: 26962600 Free Books & Documents. Review.
Riociguat has a Health Canada indication for the management of inoperable CTEPH (World Health Organization [WHO] Group 4), or persistent or recurrent CTEPH after surgical treatment in adults aged 18 years with WHO functional class II or III pulmonary hypertension. ...The o
Riociguat has a Health Canada indication for the management of inoperable CTEPH (World Health Organization [WHO] Group 4), or persist
Vericiguat for Heart Failure with Reduced Ejection Fraction.
Lombardi CM, Cimino G, Pagnesi M, Dell'Aquila A, Tomasoni D, Ravera A, Inciardi R, Carubelli V, Vizzardi E, Nodari S, Emdin M, Aimo A. Lombardi CM, et al. Curr Cardiol Rep. 2021 Aug 19;23(10):144. doi: 10.1007/s11886-021-01580-6. Curr Cardiol Rep. 2021. PMID: 34410527 Free PMC article. Review.
The sGC activator cinaciguat increases cGMP levels by direct NO-independent activation of sGC and may be particularly effective in conditions of increased oxidative stress and endothelial dysfunction, and therefore reduced NO levels, at the expense of a greater risk of hypotensio …
The sGC activator cinaciguat increases cGMP levels by direct NO-independent activation of sGC and may be particularly effective in condition …
Pharmacotherapy for pulmonary arterial hypertension.
Parikh V, Bhardwaj A, Nair A. Parikh V, et al. J Thorac Dis. 2019 Sep;11(Suppl 14):S1767-S1781. doi: 10.21037/jtd.2019.09.14. J Thorac Dis. 2019. PMID: 31632754 Free PMC article. Review.
511 results